Figure 1From: pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104 Predicted overall survival (OS) probabilities (derived from a Cox model) based on the 4 exemplary pERK IHC score levels 0, 4, 9 and 12 (n = 153; p[ log rank ] = 0.050). Back to article page